Evidence map›Paper›PMID 35601875›Full record

ArticleThe Egyptian journal of neurology, psychiatry and neurosurgery2022

Is there a difference between GBS triggered by COVID-19 and those of other origins?

Vanja Radišić, Mirjana Ždraljević, Stojan Perić, Branka Mladenović, Branislav Ralić, Dejana R Jovanović, Ivana Berisavac

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Egyptian journal of neurology, psychiatry and neurosurgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Vanja RadišićNeurology Clinic, University Clinical Center of Serbia, Dr. Subotic Street 6, 11 000 Belgrade, Serbia.
Mirjana ŽdraljevićNeurology Clinic, University Clinical Center of Serbia, Dr. Subotic Street 6, 11 000 Belgrade, Serbia.
Stojan PerićNeurology Clinic, University Clinical Center of Serbia, Dr. Subotic Street 6, 11 000 Belgrade, Serbia.
Branka MladenovićPhysical Medicine and Rehabilitation Clinic, University Clinical Center of Serbia, Pasterova Street 2, 11 000 Belgrade, Serbia.
Branislav RalićNeurology Department, CHC Zvezdara, Presevska Street 31, 11 000 Belgrade, Serbia.
Dejana R JovanovićNeurology Clinic, University Clinical Center of Serbia, Dr. Subotic Street 6, 11 000 Belgrade, Serbia.
Ivana BerisavacNeurology Clinic, University Clinical Center of Serbia, Dr. Subotic Street 6, 11 000 Belgrade, Serbia.
Centar za Promociju Nauke · RSUniversity of Belgrade · RSKliničko Bolnički Centar Zvezdara · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Since the outbreak of the coronavirus disease 2019 (COVID-19), an increasing number of Guillain-Barré syndrome (GBS) cases following the infection has been reported. The aim of our study was to detect patients with GBS treated in our hospital over a 1-year period and to compare the characteristics and outcomes of those triggered by COVID-19 with the rest of GBS patients. Our prospective study included 29 patients who were diagnosed with GBS from March 2020 to March 2021. Based on the preceding event, patients were stratified as post-COVID-19 and non-COVID-19. The GBS disability scale (GDS) was used to assess functional disability. Results: We identified 10 (34.5%) patients with post-COVID-19 GBS and 19 (65.5%) patients with non-COVID-19 GBS. The median time from the preceding event to the symptoms onset was longer in post-COVID-19 than in non-COVID-19 GBS patients ( Conclusions: There was no difference in clinical and electrophysiological features, disease course, and outcome in post-COVID-19 compared with non-COVID-19 GBS patients.

Indexed as

COVID-19Functional disabilityGuillain–Barré syndromeOutcome

Identifiers

PMID35601875
PMCPMC9107584
OpenAlexW4280589530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.